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Objective: Although cilostazol is commonly used as an adjunct after peripheral vascular interventions, its efﬁcacy remains
uncertain. We assessed the effect of cilostazol on outcomes after peripheral vascular interventions using meta-analytic
techniques.
Methods: We searched MEDLINE (1946-2012), Cochrane CENTRAL (1996-2012), and trial registries for studies
comparing cilostazol in combination with antiplatelet therapy to antiplatelet therapy alone after peripheral vascular
interventions. Treatment effects were reported as pooled risk/hazard ratio (HR) with random-effects models.
Results: Two randomized trials and four retrospective cohorts involving 1522 patients met inclusion criteria. Across
studies, mean age ranged from 65 to 76 years, and the majority of patients were male (64%-83%); mean follow-up
ranged from 18 to 37 months. Most interventions were in the femoropopliteal segment, and overall, 68% of
patients had stents placed. Pooled estimates demonstrated that the addition of cilostazol was associated
with decreased restenosis (relative risk [RR], 0.71; 95% conﬁdence interval [CI], 0.60-0.84; P < .001), improved
amputation-free survival (HR, 0.63; 95% CI, 0.47-0.85; P[ .002), improved limb salvage (HR, 0.42; 95% CI, 0.27-
0.66; P < .001), and improved freedom from target lesion revascularization (RR, 1.36; 95% CI, 1.14-1.61; P < .001).
There was no signiﬁcant reduction in mortality among those receiving cilostazol (RR, 0.73; 95% CI, 0.45-1.19;
P [ .21).
Conclusions: The addition of cilostazol to antiplatelet therapy after peripheral vascular interventions is associated with a
reduced risk of restenosis, amputation, and target lesion revascularization in our meta-analysis of six studies. Consid-
eration of cilostazol as a medical adjunct after peripheral vascular interventions is warranted, presuming these ﬁndings are
broadly generalizable. (J Vasc Surg 2014;59:1607-14.)During the past 2 decades, endovascular techniques
including angioplasty and stent placement have been incor-
porated into treatment paradigms for patients with periph-
eral arterial disease.1 Although there are advantages to
using minimally invasive techniques for the treatment of
peripheral arterial disease, the long-term durability of these
interventions remains a signiﬁcant issue. Late clinical failure
in the form of restenosis may compromise clinical out-
comes and can necessitate repeated interventions, impart-
ing additional procedural risk and cost.2
Pharmaceutical treatments may decrease postinterven-
tion restenosis within treated arterial segments,3,4 potentially
resulting in better long-term clinical outcomes and less overall
treatment cost by reducing the need for serial interventions.
Cilostazol, a phosphodiesterase inhibitor, has pleiotropic
effects including inhibition of platelet aggregation, directthe Section of Vascular Surgery, Dartmouth-Hitchcock Medical Cen-
ra; and The Dartmouth Institute for Health Policy and Clinical Practice.b
or conﬂict of interest: none.
ented at the Twenty-seventh Annual Meeting of the Eastern Vascular
ciety, White Sulphur Springs, WVa, September 21, 2013.
rint requests: Courtney J. Warner, MD, MS, Section of Vascular Sur-
ry, Dartmouth-Hitchcock Medical Center, One Medical Center Dr,
banon, NH 03756 (e-mail: courtney.j.warner@hitchcock.org).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.11.096arterial vasodilation, and prevention of intimal hyperplasia.5
Previous reports demonstrated the effectiveness of cilostazol
therapy for the prevention of restenosis after percutaneous
coronary intervention6,7 and suggested similar beneﬁt after
peripheral arterial intervention.8-14 However, no study has
summarized the current data demonstrating the effectiveness
of cilostazol in preventing restenosis or improving clinical out-
comes after peripheral endovascular interventions.
The aim of this study was to systematically review and
analyze the effect of cilostazol (in addition to antiplatelet
medication) compared with antiplatelet medication alone
in preventing restenosis and improving clinical outcomes
after endovascular therapy for lower extremity peripheral
arterial disease, speciﬁcally angioplasty and stent placement.
METHODS
Protocol and study eligibility criteria. We used
methodology recommended by the Cochrane Collabora-
tion15 to identify appropriate studies. To report our
methods and ﬁndings, we used guidelines outlined in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement.16 We included
studies of any design that met the following criteria:
1. The population studied must be patients undergoing
endovascular treatment (angioplasty or stenting) for
infrainguinal lower extremity peripheral vascular
disease.1607
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dural setting.
3. The comparison group may be no cilostazol, an anti-
platelet medication, or placebo.
4. The minimum duration of follow-up had to be
6 months.
5. The study reported at least one prespeciﬁed outcome
of interest (restenosis, freedom from amputation,
mortality).
We were unable to restrict our analysis to randomized
controlled trials (RCTs) because of the small number of
studies with this design. Comparison groups included pa-
tients taking either no cilostazol or an alternative antiplate-
let regimen (ticlopidine). We included studies of both
angioplasty and stenting, as practice patterns vary and po-
tential beneﬁt is of interest after both procedures. The min-
imum duration of follow-up was chosen on the basis of the
inherent time interval between endovascular treatment and
the development of intimal hyperplasia.
Outcome measures. Our primary outcome measure
of interest was postintervention restenosis as measured by
duplex ultrasonography, computed tomography angiog-
raphy, or angiography. Restenosis was deﬁned as a peak
systolic velocity ratio $2.413,14 or >50% vessel diameter
reduction10 on follow-up duplex ultrasound examination.
Restenosis was reported by three of the studies. Other
outcomes of interest included patency, occlusion, freedom
from target lesion revascularization, limb salvage, and
amputation-free survival. These outcomes were based on
the suggested objective performance goals for evaluating
the effectiveness of endovascular interventions in the lower
extremity.17 In addition to these potential beneﬁts, harms
including bleeding complications and adverse drug effects
were also considered important outcomes.
In each of the included studies, cilostazol therapy was
continued for the duration of follow-up. Compliance with
postprocedural cilostazol therapy was speciﬁcally detailed
in three studies reporting 94%, 100%, and 90% compliance
rates.8,10,14 Two of the studies used intention-to-treat anal-
ysis to ensure that any bias would underestimate cilostazol
beneﬁt.
Search methods and study selection. We searched
MEDLINE (1946-2012) by the Ovid search engine and
Cochrane CENTRAL (1996-2012) for potentially relevant
studies in October 2012. We used exploded medical sub-
ject headers (MeSH) terms and keywords to generate sets
for the following themes: cilostazol, restenosis, stent, periph-
eral artery disease. The terms restenosis, stent, and peripheral
artery disease were searched with the Boolean term or and
then intersected with cilostazol with the Boolean term and.
We conducted our latest search on October 31, 2012. We
considered all types of publications eligible, and no lan-
guage or other limits were applied.
To identify published and unpublished studies missed
during the primary search, we manually searched the refer-
ence lists of included articles. To identify unpublished
studies, we screened proceedings from the Society forVascular Surgery Annual Meeting between 2000 and
2012. Two unblinded reviewers independently screened ti-
tles and abstracts of the 566 articles from our initial search
for eligibility. After obtaining the published text of poten-
tially relevant articles, the same reviewers performed a
formal full-text assessment to determine ﬁnal eligibility.
Disagreements about eligibility between reviewers were
resolved with a third reviewer by discussion and consensus.
All studies that met inclusion criteria were used for data
extraction. Articles were screened for overlapping popula-
tions to avoid duplicate outcome reporting. We developed
a standardized data collection form, tested this form on
two studies that met the inclusion criteria, and reﬁned
the form accordingly. Two unblinded reviewers indepen-
dently extracted data from each included study, and a third
author checked the resulting data.
Assessment of methodological quality. We formally
assessed the methodological quality of each study with
two validity scales. For RCTs, we used the Cochrane Col-
laboration’s risk of bias assessment tool, which contains
seven domains that assess for the risk of bias in randomized
trials, each of which is categorized as low, high, or unclear
risk of bias.18 For the observational studies, we used the
Newcastle-Ottawa quality assessment scale, which allocates
stars (0-9) for the quality of population selection, compa-
rability, exposure, and outcomes.19
Analysis. We used Revman 5.1 software to analyze and
pool each outcome.20 Treatment effects for dichotomous
outcomes were assessed through comparison of the hazard
ratio (HR) and the relative risk (RR) ratio with the 95%
conﬁdence interval (CI) or P value, with each separate
outcome assessed at a 99.3% signiﬁcance level to control
type I error across the studies. For the outcome of restenosis,
we used raw event rates when necessary to allow formal data
pooling. Summary estimates of overall effects were created
by incorporating the direction, magnitude, and statistical
signiﬁcance from different studies for like outcomes.
Quantitative data summarization was performed on several
outcome categories, including patency-related, limb-related,
and mortality-related outcome groups. Adjusted outcomes
were used when available. Adjusted HRs were reported in
cohort studies, whereas RR ratios were reported in RCTs.
During analysis, we ranked outcomes by follow-up duration
and found no signiﬁcant trend or association between
duration and treatment effect.
In the event that relevant data were not provided in the
manuscript, we requested this information from the au-
thors. If these requests were not answered and adequate
data for a particular outcome could not be obtained, we
excluded the study from the analysis of that outcome.
We assessed variability among the studies by heteroge-
neity testing when three or more studies reported the same
outcome and the results were pooled. We used I2 greater
than 50% as a threshold for signiﬁcant heterogeneity. We
assessed publication bias by visually inspecting each study
for outcome effect size and sample size as well as by look-
ing for a paucity of small negative studies, which suggests
the potential for publication bias.
Fig 1. Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) ﬂow diagram.
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Patient and study characteristics. Our initial search
strategy identiﬁed 537 unique studies that we considered
for inclusion. We excluded 504 articles on the basis of
screening titles and abstracts and 27 on the basis of full-
text review. Ultimately, six studies met all inclusion criteria
(Fig 1). The Table displays the baseline characteristics of the
two RCTs and four retrospective cohorts that met inclusion
criteria. A total of 1522 patients were included in our review.
Amajority (87%) were from retrospective cohort studies. All
studies were conducted in Japan and published between
2008 and 2012. All compared cilostazol with either no cil-
ostazol10,12-14 (n ¼ 4) or an alternative antiplatelet medi-
cation8,9 (ticlopidine, n ¼ 2), with both groups receiving
various cointerventions (aspirin with or without an adjunct
antiplatelet medication). Across studies, the mean age
ranged from 65 to 76 years, and 64% to 83% were men. The
majority of interventions were in the femoropopliteal
segment (vs infrapopliteal location), and overall, 68% of
patients underwent stent placement. Mean follow-up
ranged from 18 to 37 months. The indication for inter-
vention (critical limb ischemia vs claudication) varied across
studies. In each study, patient comorbidities were balanced
in both treatment groups (in two studies, propensity score
matching was used to achieve similar comparison groups).
In one report, the entire population was hemodialysis
dependent.10
There was minimal heterogeneity from study to study
with a consistent set of ﬁndings for patency- and limb-
related outcomes. The mortality results of the retrospective
cohort studies were heterogeneous (I2 ¼ 63%). Sensitivity
analysis demonstrated that removal of studies with a major-
ity of critical limb ischemia patients yielded an acceptably
low I2. Thus, the heterogeneity among these studies is
likely to be due to the severity of underlying illness associ-
ated with patients presenting with critical limb ischemia.
Figs 2 and 3 outline the assessment of methodological
quality for each study. Overall, methodological quality wasgood. Important limitations include the retrospective na-
ture of the four observational studies with potential for
selection bias and related confounding. Two of the retro-
spective cohorts used propensity score matching to miti-
gate this risk10,13; the other two used adjustment
techniques in their regression analyses.9,12 In addition,
there was variation in the cointerventions occurring in
the cilostazol and comparison groups within the studies.
The RCTs had low risk of bias in most of the Cochrane
risk-of-bias tool domains, but the open-label design pre-
cluded blinding of the study participants and is a potential
source of performance bias.
Main ﬁndings. To organize and facilitate the merging
of outcomes reported across the studies, outcomes were
divided into three broad categories: patency-related out-
comes (including restenosis, patency, and occlusion), limb-
related outcomes (including limb salvage, amputation-free
survival, and freedom from target lesion revascularization),
and mortality-related outcomes. Outcomes from both
RCTs and retrospective cohort studies were collectively
considered. The follow-up interval associated with these
outcomes ranged from 2 to 6 years.
Patency-related outcomes. Two studies comparing
cilostazol with ticlopidine reported patency; both favored
cilostazol (75% vs 30% at 2 years; P ¼ .007, and 73% vs
51% at 3 years; P ¼ .01, respectively).8,9 Restenosis was
reported across three studies (Fig 4). In one RCT, cilostazol
was associated with a decreased risk of restenosis compared
with no cilostazol at 2 years (RR, 0.62; 95% CI, 0.41-0.94;
P ¼ .02).14 Similar ﬁndings were shown in the two retro-
spective cohort studies. The ﬁrst study reported an adjusted
HR for restenosis of 0.60 at 5 years (95%CI, 0.43-0.84; P¼
.003), with a calculated risk ratio of 0.73 (95% CI, 0.58-
091; P ¼ .02).13 The second study demonstrated a
decreased risk of restenosis at 6 years with an HR of 0.51
(95%CI, 0.27-0.84; P¼ .008), with a calculated risk ratio of
0.74 (95% CI, 0.54-1.01; P ¼ .05).11 When combined by
meta-analytic techniques, the summary estimate demon-
strated lower rates of restenosis in patients taking cilostazol
(RR, 0.71; 95% CI, 0.60-0.84; P < .001; Fig 5).
Vessel occlusion was reported in two studies. The rate
of in-stent occlusion in one of the RCTs was 5.1% in the
cilostazol group vs 16.2% in the group not receiving cilos-
tazol at 2 years, but this was not statistically signiﬁcant (P ¼
.12).14 However, in the cohort study reporting occlusion,
cilostazol was associated with reduced in-stent occlusion
at 5 years with an adjusted HR of 0.55 (95% CI, 0.31-
0.97; P ¼ .04).13
Limb-related outcomes. Limb-related outcomes re-
ported in two or more studies included freedom from
target lesion revascularization, amputation-free survival,
and limb salvage.
Freedom from target lesion revascularization was
improved in the cilostazol groups with RR 1.40 (95%
CI, 1.10-1.78; P ¼ .04) and RR 1.31 (95% CI, 1.02-
1.68; P < .05) at 2 and 3 years, respectively.8,14
Amputation-free survival was improved in the cilostazol
group in both studies reporting this outcome with HR
Table. Characteristics of included studies
Author Year Design No.
Age,
years
Male,
%
Indication,
% CLIa
Lesion
location, %
femoropoplitealb
Intervention,
% stentc Comparisond Cointerventiond
Mean
follow-up,
months
Soga 2011 Retrospective
cohort
618 72 6 11 69% 100% 35% 37% No
cilostazol
Aspirin,
clopidogrel
21
Soga 2012 Retrospective
cohort
562 73 6 9 76% 26% 100% 100% No
cilostazol
Aspirin,
clopidogrel
25
Ikushima 2011 Retrospective
cohort
28 76 6 7 82% 36% 100% 100% Ticlopidine Aspirin 18
Iishi 2010 Retrospective
cohort
109 65 6 11 64% 21% 100% 65% No
cilostazol
Aspirin 37
Soga 2009 RCT 78 71 6 8 83% 0% 100% 46% No
cilostazol
Aspirin,
ticlopidine
24
Iida 2008 RCT 127 70 6 8 72% 25% 100% 87% Ticlopidine Aspirin 36
CLI, Critical limb ischemia; RCT, randomized controlled trial.
aIndications included critical limb ischemia vs claudication.
bLesion locations include femoropopliteal and infrapopliteal.
cInterventions include stenting (with or without angioplasty) and angioplasty alone.
dAspirin dose, 81-200 mg/day; ticlopidine dose, 200 mg/day; clopidogrel dose, 75 mg/day.
Fig 2. Newcastle-Ottawa quality assessment scale.
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0.19-0.98; P < .05) at 5 and 6 years, respectively.10,12
Finally, limb salvage at 5 years in patients with critical
limb ischemia was reported in two cohort studies. In the
ﬁrst study, cilostazol was associated with improved limb
salvage (adjusted HR, 0.42; 95% CI, 0.26-0.69; P <
.001).12 In the second study, there was a trend toward
improved limb salvage, but this was not statistically signif-
icant (adjusted HR, 0.44; 95% CI, 0.17-1.14; P ¼ .09).13
The summary estimates signiﬁcantly favor cilostazol for
each set of limb-related outcomes (freedom from target
lesion revascularization, amputation-free survival, and
limb salvage). When combined by meta-analytic tech-
niques, the summary estimate for freedom from target
lesion revascularization is RR 1.36 (95% CI, 1.14-1.61;
P < .001); for amputation-free survival, HR 0.63 (95%
CI, 0.47-0.85; P ¼ .002); and for limb salvage, HR 0.42
(95% CI, 0.27-0.66; P < .001; Fig 5).
Mortality-related outcomes. Mortality-related out-
comes were reported in ﬁve studies. In both RCTs, cilosta-
zol therapy had no signiﬁcant effect on mortality at 2 years
(RR, 0.50; 95% CI, 0.05-5.29; P ¼ .6) and 4 years (RR,
0.68; 95% CI, 0.20-2.29; P ¼ .53).8,14 The retrospective
cohort studies demonstrated similar results, with no dif-
ference in all-cause mortality at 5 years (HR, 0.7; 95% CI,0.42-1.17; P ¼ .2)13 and no difference in overall survival at
5 years (HR, 1.04; 95% CI, 0.74-1.47; P ¼ .84)12 between
the cilostazol and comparison groups. One study, however,
documented improvement in overall survival among the
patients in the cilostazol group (HR, 0.41; 95% CI, 0.19-
0.88; P ¼ .02).10 The summary estimates calculated for
mortality-related outcomes showed no signiﬁcant differ-
ence between the cilostazol and comparison groups in both
the RCTs (RR, 0.64; 95% CI, 0.22-1.87; P ¼ .4) and
cohort studies (HR, 0.73; 95% CI, 0.45-1.19; P ¼ .2)
(Fig 6).
Regarding adverse drug effects, one RCT found no dif-
ference in bleeding complications between the cilostazol
and ticlopidine groups.8 Adverse drug effects reported in
three of the studies included palpitations (7%), headache
(4%), and peripheral edema (2%).8,10,14DISCUSSION
Main ﬁndings. Improving the durability of endo-
vascular interventions is important, as these procedures
are common and treatment failure can have severe
consequences. In the current review, we attempt to sys-
tematically evaluate the available evidence on the ef-
fectiveness of cilostazol to improve durability and to
Fig 3. Cochrane risk-of-bias tool.
Fig 4. Restenosis after peripheral vascular intervention (PVI).
RCT, Randomized controlled trial.
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vascular interventions.
Across studies, patients treated with cilostazol after pe-
ripheral intervention consistently experienced improved
patency- and limb-related outcomes. Whereas patency and
mortality are important, limb-related outcomes may best
capture outcomes most important to patients after periph-
eral vascular interventions. In the groups receiving cilosta-
zol, there were improvements in limb salvage, freedomfrom target lesion revascularization, and amputation-free
survival across multiple studies. Overall, there was no signif-
icant improvement in mortality-related outcomes (death,
cardiovascular death, overall survival) across studies, with
the exception of one retrospective study reporting increased
survival in patients receiving cilostazol.
The ﬁndings of improved patency- and limb-related
outcomes were consistent across studies despite variation
in indication, intervention, and comparison. Associations
between cilostazol and improved freedom from target
lesion revascularization were established by RCT; associa-
tions between cilostazol and improved limb salvage and
amputation-free survival were established from retrospec-
tive cohort data. Whereas the consistency of these ﬁndings
provides important information about the effectiveness of
cilostazol, all studies were performed in a similar setting
(Japan), where the pharmaceutical company that markets
cilostazol is located. Given the inherent differences in pop-
ulation demographics and exposures between Japan and
other settings, there may be inadequate evidence to gener-
alize ﬁndings from one population to heterogeneous pop-
ulations worldwide.
In general, the included studies showed improvement in
patency-related outcomes andminimal impact onmortality-
related outcomes with cilostazol therapy. These results are
similar to those of several large meta-analyses reported in
the cardiology literature regarding cilostazol after percuta-
neous coronary intervention, documenting decreased reste-
nosis and improved freedom from revascularization in this
population.6,7 Two studies of cilostazol after peripheral
intervention narrowly missed meeting inclusion criteria
(because of inclusion of iliac interventions and inadequate
length of follow-up) but drew similar conclusions about
the beneﬁt of cilostazol.11,21
Whereas these results support the consideration of
cilostazol as a medical adjunct after peripheral interven-
tion, there are several potential barriers to promoting
cilostazol use in appropriate candidates in a real-world
clinical environment. Cost may be a signiﬁcant issue for
some patients, as the purchase price for cilostazol ranges
from approximately $4 to $5 per day.22 Previous reports
have established the relative safety of cilostazol and an
acceptable low risk of serious side effects and no increase
in bleeding events over placebo,23,24 but polypharmacy
and compliance are concerns in this patient population,
as medication regimens become increasingly complex.
Further, across the studies, harms of cilostazol were not
consistently addressed.
Limitations. The six studies that met inclusion criteria
differed in several important ways. The indication for inter-
vention varied from 100% critical limb ischemia to 100%
claudication, with several studies reporting a mixed popula-
tion. Whereas measures like amputation-free survival are
important in patients with critical limb ischemia, the event
rate is low in claudicants, and this outcome may not be
accurately reﬂected in this population. Mortality was a rare
outcome, leading to wide conﬁdence intervals and thus low
precision in summary estimates. This meta-analysis may be
Fig 5. Forest plot of main outcomes. CI, Conﬁdence interval.
Fig 6. Forest plot of mortality outcomes. CI, Conﬁdence interval; RCT, randomized controlled trial.
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and mortality. Within the studies, outcomes were not
stratiﬁed by presenting symptoms (claudication vs critical
limb ischemia) or treated segment (femoropopliteal vs
infrapopliteal), limiting our ability to study these patient
subgroups separately.
The type of intervention also varied between studies:
the majority was femoropopliteal stent placement, but
balloon angioplasty of femoropopliteal and tibial arteries
was included in several studies. The studies also varied in
their comparisons and cointerventions. Four studies
compared cilostazol with no cilostazol, whereas two studies
compared cilostazol with ticlopidine, an antiplatelet medi-
cation. Aspirin was an important cointervention providedin both arms of each study, and depending on surgeon
preference, clopidogrel was given as a cointervention to
both groups in some studies. Despite these differences in
comparison groups and cointerventions, the studies had
similar outcomes: improvement in patency and freedom
from target lesion revascularization with no signiﬁcant dif-
ference in mortality.
In general, the quality of the evidence was good with
low risk of bias across most RCT domains and high-
quality scores for the retrospective cohort studies. However,
the RCTs were open label, and sample sizes were relatively
small (n ¼ 80 and n ¼ 127). Lack of blinding within the
RCT and cohort studies is a signiﬁcant potential source of
bias. There may be patient characteristics that inﬂuenced
JOURNAL OF VASCULAR SURGERY
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ducing unmeasured selection bias. Overall, the consistency
of the results across studies allowed us to integrate out-
comes, enhancing the internal validity of the review.
Adjusted results were used whenever possible to minimize
the potential for confounding.
One important consideration is the potential for publi-
cation bias; all reviewed studies demonstrated signiﬁcant
beneﬁt in one or more of the outcomes measured. The
assessment of publication bias is difﬁcult, as few studies
met our inclusion criteria. To minimize this bias, our search
strategy included abstracts, trial registries, and meeting
proceedings in an attempt to minimize publication bias
and to ﬁnd all relevant studies, and no studies or abstracts
reported lack of a positive ﬁnding (or any negative ﬁnding)
between cilostazol and outcome.
Other factors related to the introduction of bias
included variability in the measuring and reporting of out-
comes, necessitating qualitative analysis with limited formal
statistical pooling of data. Several authors were contacted
for additional data about unreported outcomes without
success; thus, there were often only two or three studies
reporting a given outcome. Further, our strict inclusion
criteria precluded the use of some potentially relevant
data. One study included iliac artery interventions11;
although the main results were similar to those of other
studies included in our review, iliac interventions have bet-
ter patency-related outcomes, and this study was not
included. A second study on cilostazol administration after
tibial angioplasty had 3-month follow-up21; we thought it
inappropriate to include this as the time interval in which to
observe restenosis may be inadequate.
CONCLUSIONS
On the basis of available evidence, adding cilostazol to
antiplatelet therapy after endovascular interventions for
lower extremity peripheral arterial disease is associated
with improved patency- and limb-related outcomes, result-
ing in decreased restenosis as well as improved limb salvage,
amputation-free survival, and freedom from target lesion
revascularization. Consideration of cilostazol as a medical
adjunct in appropriate candidates is warranted to poten-
tially improve limb-related outcomes and durability after
lower extremity angioplasty and stent placement for pe-
ripheral arterial disease. All of the studies reviewed on cilos-
tazol after peripheral interventions were performed in a
similar setting in Japan, and the majority of these studies
were retrospective in nature. Further RCTs on heteroge-
neous populations are needed to investigate the generaliz-
ability of these ﬁndings.
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